PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer.

Abstract Accumulated evidence has demonstrated that Mammalian hepatitis B X-interacting protein (HBXIP) has broad roles in cancer. Although HBXIP is associated with a variety of cancers, the HBXIP protein expression level and its clinical significance in ovarian cancer have not yet been determined. The aim of this study is to investigate the association between HBXIP expression and the clinicopathological features of ovarian cancer patients to determine whether HBXIP may be correlated with a poor prognosis in ovarian cancer patients.
PMID
Related Publications

NQO1 protein expression predicts poor prognosis of non-small cell lung cancers.

The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.

HBXIP over expression as an independent biomarker for cervical cancer.

HBXIP expression in gastric adenocarcinoma predicts poor prognosis.

HBXIP expression predicts patient prognosis in breast cancer.

Authors

Mayor MeshTerms
Keywords

Hepatitis B virus X-interacting protein

Immunohistochemistry

Ovarian cancer

Survival analysis

Journal Title journal of ovarian research
Publication Year Start




PMID- 28388957
OWN - NLM
STAT- MEDLINE
DA  - 20170408
DCOM- 20170418
LR  - 20170418
IS  - 1757-2215 (Electronic)
IS  - 1757-2215 (Linking)
VI  - 10
IP  - 1
DP  - 2017 Apr 07
TI  - HBXIP overexpression is correlated with the clinical features and survival
      outcome of ovarian cancer.
PG  - 26
LID - 10.1186/s13048-017-0322-7 [doi]
AB  - BACKGROUND: Accumulated evidence has demonstrated that Mammalian hepatitis B
      X-interacting protein (HBXIP) has broad roles in cancer. Although HBXIP is
      associated with a variety of cancers, the HBXIP protein expression level and its 
      clinical significance in ovarian cancer have not yet been determined. The aim of 
      this study is to investigate the association between HBXIP expression and the
      clinicopathological features of ovarian cancer patients to determine whether
      HBXIP may be correlated with a poor prognosis in ovarian cancer patients.
      METHODS: HBXIP protein expression was assessed in a well-characterized series of 
      ovarian cancer tissue samples (n = 120) with long-term follow-up, using
      immunohistochemistry to determine the location pattern and expression of HBXIP in
      ovarian cancer. The localization of HBXIP was detected in SKOV-3 ovarian cancer
      cells using immunofluorescence (IF) staining. The relationship between high HBXIP
      expression and the clinicopathological features of ovarian cancer patients was
      analyzed by Chi-square and Fisher's exact test. Overall survival (OS) rates of
      all the ovarian cancer patients were calculated using the Kaplan-Meier method,
      and univariate and multivariate analyses were performed using the Cox
      proportional hazards regression model. RESULTS: IF staining revealed strongly
      positive signals for HBXIP in both cytoplasm and nucleus, but mainly in the
      cytoplasm of SKOV-3 ovarian cancer cells. High HBXIP expression was predominantly
      observed in ovarian cancer tissues but not the adjacent non-tumor ovarian
      tissues. The strongly positive rate of HBXIP expression was 60.0% (72/120) in
      ovarian cancer and was significantly higher than in adjacent non-tumor tissues
      (17.4%, 4/23) (P = 0.000). High HBXIP expression was positively correlated with
      the occurrence of lymph node metastases (P = 0.025), histological grade (P =
      0.036) and clinical stage (P = 0.003). The patients with high HBXIP expression
      had lower overall survival (OS) rates. Moreover, multivariate analysis indicated 
      that HBXIP, in addition to the clinical stage, was a significant independent
      prognostic factor in patients with ovarian cancer. CONCLUSIONS: High-level
      expression of HBXIP is associated with the progression of ovarian cancer and may 
      be an effective biomarker for poor prognostic evaluation as well as a potential
      molecular therapy target for ovarian cancer patients.
FAU - Wang, Yixuan
AU  - Wang Y
AD  - Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, 
      Yanbian University, Yanji, 133002, Jilin, China.
AD  - Department of Pathology & Cancer Research Center, Yanbian University Medical
      College, Yanji, 133002, Jilin, China.
FAU - Sun, Jie
AU  - Sun J
AD  - Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, 
      Yanbian University, Yanji, 133002, Jilin, China.
AD  - Department of Pathology & Cancer Research Center, Yanbian University Medical
      College, Yanji, 133002, Jilin, China.
FAU - Li, Nan
AU  - Li N
AD  - Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, 
      Yanbian University, Yanji, 133002, Jilin, China.
FAU - Che, Shuanlong
AU  - Che S
AD  - Department of Pathology & Cancer Research Center, Yanbian University Medical
      College, Yanji, 133002, Jilin, China.
FAU - Jin, Tiefeng
AU  - Jin T
AD  - Department of Pathology & Cancer Research Center, Yanbian University Medical
      College, Yanji, 133002, Jilin, China.
FAU - Liu, Shuangping
AU  - Liu S
AD  - Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, 
      Yanbian University, Yanji, 133002, Jilin, China. [email protected]
AD  - Department of Pathology & Cancer Research Center, Yanbian University Medical
      College, Yanji, 133002, Jilin, China. [email protected]
FAU - Lin, Zhenhua
AU  - Lin Z
AD  - Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, 
      Yanbian University, Yanji, 133002, Jilin, China. [email protected]
AD  - Department of Pathology & Cancer Research Center, Yanbian University Medical
      College, Yanji, 133002, Jilin, China. [email protected]
LA  - eng
PT  - Journal Article
DEP - 20170407
PL  - England
TA  - J Ovarian Res
JT  - Journal of ovarian research
JID - 101474849
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HBXIP protein, human)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/*biosynthesis
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/biosynthesis
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Middle Aged
MH  - Ovarian Neoplasms/*metabolism/pathology
MH  - Prognosis
MH  - Survival Analysis
PMC - PMC5384129
OTO - NOTNLM
OT  - Hepatitis B virus X-interacting protein
OT  - Immunohistochemistry
OT  - Ovarian cancer
OT  - Survival analysis
EDAT- 2017/04/09 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/09 06:00
PHST- 2016/12/23 [received]
PHST- 2017/03/29 [accepted]
AID - 10.1186/s13048-017-0322-7 [doi]
AID - 10.1186/s13048-017-0322-7 [pii]
PST - epublish
SO  - J Ovarian Res. 2017 Apr 7;10(1):26. doi: 10.1186/s13048-017-0322-7.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>